Industry
Biotechnology
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
Loading...
Open
1.65
Mkt cap
10M
Volume
8.9K
High
1.66
P/E Ratio
-0.43
52-wk high
3.20
Low
1.64
Div yield
N/A
52-wk low
1.50
Portfolio Pulse from Benzinga Insights
May 10, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 7:49 pm
Portfolio Pulse from Charles Gross
December 28, 2023 | 9:23 pm
Portfolio Pulse from Benzinga Newsdesk
September 22, 2023 | 8:43 pm
Portfolio Pulse from Lisa Levin
July 11, 2023 | 11:37 am
Portfolio Pulse from Happy Mohamed
May 24, 2023 | 12:04 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.